Filing identity and reporting period
The supplied filing is OvaScience, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed February 27, 2014. It is not identified as a Tempest Therapeutics filing; the company and period in the request metadata do not match the filing text. The filing includes unaudited quarterly results for Q4 2013.
Business context
OvaScience was a development-stage life science company developing fertility treatments based on egg precursor cells. Its lead program, AUGMENT, was intended to use a patient’s own mitochondria in IVF; OvaPrime and OvaTure were earlier-stage programs. The company had not generated commercial revenue.
Financial results and liquidity
| Metric | FY 2013 | FY 2012 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $15.8 million | $6.3 million |
| General and administrative expense | $13.3 million | $7.2 million |
| Total operating expenses | $29.1 million | $13.5 million |
| Net loss | $29.0 million | $13.5 million |
| Net loss per share, basic and diluted | $1.80 | $2.33 |
Q4 2013 operating expenses were $11.0 million and net loss was $11.0 million, including a $4.7 million Intrexon technology-access charge. Revenue and operating margins were not applicable because the company had no revenue.
Cash, cash equivalents and short-term investments totaled $44.4 million at year-end, versus $31.4 million a year earlier; working capital was $39.3 million. Operating cash use was $18.1 million in 2013, compared with $11.2 million in 2012. Financing provided $32.4 million, principally from a common-stock placement. The filing reports no material borrowings; total liabilities were $5.8 million, mainly current payables and accruals. Management expected year-end cash and investments to fund its current operating plan into 2015, but said additional funding would be needed for 2015 and beyond.
Material changes and unusual items
- Net loss more than doubled year over year as R&D and G&A expenses increased. R&D rose 150%, reflecting expanded development activity, hiring, contract research costs, the Intrexon access fee and a laboratory-equipment impairment.
- G&A increased 85%, including higher compensation and stock-based compensation, professional and consulting costs, and commercial-launch preparation.
- The March 2013 common-stock placement generated $32.7 million in net proceeds. In December, OvaScience issued 273,224 shares to Intrexon as part of the OvaTure collaboration consideration.
- A $0.4 million laboratory-equipment impairment was recorded in Q3 2013 after a manufacturer transition. Q4 included the $4.7 million Intrexon technology-access charge, comprising stock consideration and the present value of a $2.5 million cash payment due in December 2014.
- OvaScience and Intrexon each contributed $1.5 million to the 50/50 OvaXon joint venture; OvaScience recorded its contribution as an equity-method investment.
Outlook, risks and contingencies
- Management planned an international AUGMENT access program in 2014 across at least four regions, targeting 40–60 cycles, with a possible transition to commercial centers by year-end. OvaPrime was targeted for launch outside the United States in 2015. These were plans, not assured outcomes.
- The FDA’s September 2013 untitled letter questioned whether AUGMENT qualified as a 361 HCT/P and advised the company to file an IND. OvaScience suspended enrollment in its U.S. AUGMENT study and planned further FDA discussions. A different regulatory classification could require costly studies and approvals, delay commercialization or lead the company to abandon U.S. development.
- The company warned that its science was novel, human evidence was limited, and OvaPrime and OvaTure had not been tested in humans. Clinical or preclinical results, safety, regulatory decisions, manufacturing capacity and market acceptance remained uncertain.
- OvaScience relied on third parties for manufacturing and expected limited insurance reimbursement; out-of-pocket affordability could constrain demand. It anticipated continuing losses and no material revenue before the second half of 2014, if ever, and had no committed external funding source.
- A purported shareholder class action concerning AUGMENT disclosures was voluntarily dismissed without prejudice in February 2014. The filing reported no other pending litigation known to management.
- Management stated that disclosure controls and internal control over financial reporting were effective at December 31, 2013. The auditor did not provide an internal-control attestation.
Key facts investors should verify
- Confirm the filing belongs to OvaScience, Inc., not Tempest Therapeutics, and that the relevant period is FY 2013 rather than a standalone Q4 filing.
- Check subsequent cash use, financing, dilution and whether the stated runway into 2015 was achieved.
- Verify the FDA’s eventual regulatory position on AUGMENT and the status, results and safety evidence for its studies and international program.
- Assess whether OvaPrime and OvaTure met development milestones, and whether any program generated revenue or required additional funding.
- Review the Intrexon payment, royalty and milestone obligations, manufacturing arrangements, and any later developments in the dismissed lawsuit.